Today: 22 December 2025
Subscribe
Browse Category

Biotechnology News 27 November 2025 - 5 December 2025

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon Ltd. (NASDAQ: PLRZ) has gone from obscure micro‑cap to headline‑grabbing biotech in just two trading days. On December 4, 2025, the stock was changing hands in the mid‑teens, more than doubling from the prior close of $7.09, with intraday
4 December 2025
 ·  ·  ·  ·  · 
Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Updated: December 4, 2025 – mid‑day U.S. trading Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just pulled off the kind of move small‑cap biotech traders dream about and risk managers lose sleep over. After releasing decisive Phase 3 data for its
4 December 2025
 ·  ·  ·  ·  · 
Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight. On December 3, 2025, the pharma giant’s share price jumped more than 6% intraday to around $51.32, extending a multi‑day rebound driven by a mix of clinical trial news, AI‑driven
3 December 2025
 ·  ·  ·  ·  · 
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD) met both its primary and key secondary endpoints. GlobeNewswire Below is a
3 December 2025
 ·  ·  ·  ·  · 
Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (PLRZ) Stock Soars on Nasal Spray Milestone: Latest News, AI Forecasts and Risk Outlook – December 3, 2025

Polyrizon Ltd (NASDAQ: PLRZ) has suddenly jumped from obscure micro‑cap to headline mover. On Tuesday, December 2, 2025, the Israeli biotech’s shares spiked roughly 130% in a single session after the company announced a key manufacturing upscaling milestone for its
3 December 2025
 ·  ·  ·  ·  · 
ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

ImmunityBio (IBRX) Stock Soars After Q3 Revenue Explosion – Can the Rally Survive a Going‑Concern Warning?

Published: November 29, 2025 ImmunityBio, Inc. (NASDAQ: IBRX) has jumped back onto traders’ and long‑term investors’ radar after a powerful late‑November rally in its share price, driven by blockbuster third‑quarter numbers for its cancer drug Anktiva and a wave of
29 November 2025
 ·  ·  ·  ·  · 
HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025

HKEX (388) Stock Today: Hong Kong Exchanges & Clearing Holds Near HK$415 Ahead of Biotech Futures Launch – 27 November 2025

Hong Kong Exchanges & Clearing Limited (HKEX, stock code 388, ticker 0388.HK) traded slightly higher on Thursday, as investors digested a packed calendar of derivatives expiries, fresh sustainable‑finance headlines and the imminent launch of Hang Seng Biotech Index futures. The
27 November 2025
 ·  ·  ·  · 
1 … 3 4 5 6 7 … 15
Go toTop